Alkermes(ALKS)
Focus: Alkermes is a Dublin-headquartered public biotech company specializing in small-molecule therapeutics across neurology, psychiatry, and metabolic diseases. The company generates $1.7B in revenue with a highly concentrated portfolio where ARISTADA accounts for 63% of sales.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
25
Should You Work at Alkermes?
AI assessmentBest fit for commercial and engineering professionals seeking stability within a focused, psychiatry-led biotech; riskier for R&D careers given pipeline quality vs. concentration dependency.
Why Work Here
- Strong revenue trajectory: FY2025 revenue of $1.7B (+55% YoY) with $356M net income signals financial stability and investment capacity
- Commercial growth engine: 12 open Commercial roles indicate aggressive market expansion for peak-stage products with long patent runways (ARISTADA through 2039, LYBALVI through 2041)
Data completeness
7/9 — Strong
Company HealthStrong
Pipeline
Late-stage
9 Phase 3+
LOE Risk
1 in 5yr
VIVITROL
Hiring
Stable
Revenue
$1.7B
Key Products
$273M Part DStable
Peak12.9yr
Cornerstone product with long exclusivity runway; long-acting injectable format provides differentiation and patient adherence benefits.
Help build intelligence for Alkermes
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.